Axalta's second quarter arrived three weeks before the vote that will end Axalta as a standalone public company. The numbers management delivered to the market on July 28 - a record $305 million of Adjusted EBITDA, a record $0.72 of Adjusted Diluted EPS, a 22.7% Adjusted EBITDA margin up 30 basis points year over year, $107 million of free cash flow, and the lowest total net leverage in company history at 2.2 times - were the cleanest operating print the company has ever filed. Reported revenue rose 3% to $1.35 billion, dragged by an incremental $31 million of merger-and-acquisition costs that flipped GAAP operating income down 14% to $167 million and GAAP diluted EPS down 18% to $0.41; strip those deal costs, and the quarter is the opposite story. The AkzoNobel shareholders vote August 5 on the all-stock combination announced in November 2025 and amended twice since; Axalta's shareholders approved it on August 5, and the combined company - MergeCo, dual-headquartered in Amsterdam and Philadelphia - is expected to close in late 2026 or early 2027 at a fixed 0.6539 AkzoNobel share for each Axalta share. The question for an investor at $37.31 is not whether Axalta's standalone franchise is healthy - the quarter answered that - but how the market is pricing the seven months of standalone runway between now and a deal that, on AkzoNobel's current EUR 73 share price (about US$78 at ~1.07 EUR/USD), implies a take-out near US$51 for Axalta, a 36% premium to the current price and roughly 77% above the unaffected 30-day average close of ~US$29 leading into the November 2025 deal announcement. The standalone fundamentals and the merger arbitrage now sit on the same ticker, and the report frame is which one moves first.